Because of our singular focus on providing nutrition-related care to our clients, we have been able to develop an expertise in nutrition-related issues and client care
Back McLean, BA, Wong, CK, Campbell, JE, et al (2021) 'Revisiting the complexity of GLP-1 action from sites of synthesis to receptor activation', Endocrine Reviews , 42/2, 101-32
Your digestive system needs time to adjust
In 2021, Novo Nordiskwhich also markets the GLP-1 receptor agonist semaglutide as Rybelsus for T2Dlaunched two Phase III trials, EVOKE and EVOKE Plus, studying the drug in approximately 3,700 people with early-stage Alzheimers disease
Christoffersen B, Sanchez-Delgado G, John LM, Ryan DH, Raun K, Ravussin E (2022) Beyond appetite regulation: targeting energy expenditure, fat oxidation, and lean mass preservation for sustainable weight loss